Nicotinamide,
does it really help with NAD+ replenishment and delayed aging?
research showsNicotinamide prevents and corrects pellagra and reduced nonmelanoma skin cancers by 23% in the high-risk ONTRAC population, but those benefits do not establish NAD+ boosting or delayed aging in the general population. In a 2026 direct-comparison trial of 65 participants, the 17-person nicotinamide arm receiving 500 mg/day did not achieve a sustained rise in circulating NAD+ after 14 days, while the NR and NMN arms did. The general longevity claim is grade D.
ads claimClaims such as 'inexpensive NAD booster,' 'reverses cellular age,' or 'works like NR and NMN' turn precursor chemistry and trials of other compounds into clinical lifespan effects. Nicotinic-acid lipid effects, NR, NMN, and nicotinamide skin-cancer prevention are separate evidence axes.
Useful facts when choosing a product
- In Korea, oral products are sold as vitamin B3 or niacinamide alone or in multivitamins; oral products must be distinguished from cosmetic niacinamide.
- The ONTRAC dose was 500 mg twice daily, totaling 1,000 mg/day.
- Ordinary nutritional doses differ greatly from the pharmacologic dose studied in high-risk skin-cancer patients.
- Nicotinamide, nicotinic acid, NR, and NMN are related but their clinical evidence is not interchangeable.
- High doses can raise concerns about gastrointestinal symptoms, liver toxicity, glucose changes, and thrombocytopenia and warrant medical advice.
What the research actually shows
The 2026 Christen randomized open-label placebo-controlled direct-comparison trial analyzed 65 healthy participants. The 17-person nicotinamide arm received 500 mg/day and did not sustain an increase in circulating NAD+ after 14 days, while the NR and NMN arms did. ONTRAC enrolled 386 high-risk participants and found a 23% reduction in new nonmelanoma skin cancers during 12 months at 500 mg twice daily. The 2021 Connell study used a mixture of tryptophan, nicotinic acid, and nicotinamide in 14 participants, so standalone attribution is weak; it was null for muscle NAD+, mitochondrial, and functional outcomes.
Why this is classified as D (35)
In a direct comparison of healthy adults, nicotinamide at 500 mg/day failed to sustain circulating NAD+ after 14 days, and no clinical aging or lifespan outcome exists. A-grade pellagra correction and B-grade ONTRAC prevention are retained as separate subclaims, while general NAD+ boosting and delayed aging receive D with 35 points. Evidence for NR, NMN, and nicotinic acid was not pooled.
Counterpoint. Evidence supports medical use for vitamin B3 deficiency and a specific recurrent-skin-cancer high-risk population. That is not evidence for longevity supplementation in healthy people.
Rejudgment record. Reassessment (cross-check reflected) — Separated pellagra and high-risk skin-cancer benefits and applied the failure of sustained NAD+ elevation in the 2026 direct comparison plus absent clinical aging outcomes; evidence for NR, NMN, and nicotinic acid was not pooled
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Prevention and correction of pellagra | A | An established nutrient effect for correcting vitamin B3 deficiency. |
| Prevention of nonmelanoma skin cancer in a high-risk population (ONTRAC) | B | ONTRAC reported a 23% reduction, PMID 26488693 |
| Delayed aging, lifespan extension, and NAD+ boosting in the general population | D | No sustained NAD+ increase and no clinical outcomes |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Christen et al. (2026) | Randomized open-label placebo-controlled four-arm direct-comparison trial, 14 days | 17 | Authors employed by Nestlé Research and Nestlé Health Science | Circulating whole-blood NAD+ and NAD+ metabolites | Nicotinamide at 500 mg/day did not sustain circulating NAD+ after 14 days; only NR and NMN increased it | Key counterevidence for general NAD+ boosting |
| Chen AC et al. 2015 (ONTRAC) | Phase 3 randomized double-blind placebo-controlled trial, 12 months | 386 | Publicly funded by the Australian NHMRC | New nonmelanoma skin cancers and actinic keratoses | New nonmelanoma skin cancers were reduced by 23% during treatment; no post-treatment benefit remained. | Key for a subclaim |
| Connell NJ et al. 2021 | Randomized double-blind controlled crossover trial, 32 days | 14 | Danone Research produced and packaged the study products | Primary mitochondrial oxidative capacity and exercise efficiency outcomes, plus muscle NAD+ | The mixed NAD+ precursor intervention did not improve primary outcomes or muscle NAD+. | Key for the longevity axis |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-16).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-16 · Corrections: none
Cite this verdict
[Chamgap] Nicotinamide (niacinamide) × NAD+ replenishment and delayed aging — Evidence Grade D·35. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/antioxidant-aging/nicotinamide-nad-longevity/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.